Recent Company News

• 12:34 AM ET Apr 01, 2026
  

  Lonza Group publishes 2025 Sustainability Report (CHF 504.80, 0.00)

• 06:05 AM ET Mar 26, 2026
  

  Kodiak Sciences announces topline results in the GLOW2 Phase 3 superiority study of Zenkuda ($22.75, 0.00)

• 08:33 AM ET Mar 23, 2026
  

  Vaxcyte completes enrollment of OPUS-1 and OPUS-2 phase 3 trials evaluating VAX-31 for the prevention of invasive pneumococcal disease and pneumonia in adults ($54.72, 0.00)

• 04:55 AM ET Mar 23, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (316 total)

• 07:51 PM ET Mar 18, 2026
  

  Vaxcyte VAX-31 Phase 1/2 adult data results published in The Lancet Infectious Diseases ($54.28, 0.00)

• 02:09 PM ET Mar 16, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 9-Mar

• 01:53 AM ET Mar 11, 2026
  

  Lonza Group to go on the offensive after selling Capsules & Health Ingredients business - FuW (CHF 496.50, 0.00)

• 02:30 AM ET Mar 10, 2026
  

  Lonza Group resumed neutral at BofA (CHF 498.70, 0.00)

• 02:00 PM ET Mar 09, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 2-Mar

• 10:16 AM ET Mar 09, 2026
  

  StreetAccount M&A Summary: Week of 2-Mar